L1-CAM knock-down radiosensitizes neuroblastoma IMR-32 cells by simultaneously decreasing MycN, but increasing PTEN protein expression

Rached,Johnny; Nasr,Zeina; Abdallah,Jad; Abou-Antoun,Tamara

doi:10.3892/ijo.2016.3625

L1-CAM knock-down radiosensitizes neuroblastoma IMR-32 cells by simultaneously decreasing MycN, but increasing PTEN protein expression

Authors:
- Johnny Rached
- Zeina Nasr
- Jad Abdallah
- Tamara Abou-Antoun
View Affiliations

Affiliations: Faculty of Sciences, University of Balamand, Koura, Lebanon, School of Pharmacy, Pharmaceutical Sciences Department, Lebanese American University, Byblos, Lebanon
Published online on: July 18, 2016 https://doi.org/10.3892/ijo.2016.3625
Pages: 1722-1730

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Childhood neuroblastoma is one of the most malignant types of cancers leading to a high mortality rate. These cancerous cells can be highly metastatic and malignant giving rise to disease recurrence and poor prognosis. The proto-oncogene myelocytomatosis neuroblastoma (MycN) is known to be amplified in this type of cancer, thus, promoting high malignancy and resistance. The L1 cell adhesion molecule (L1-CAM) cleavage has been found upregulated in many types of malignant cancers. In the present study, we explored the interplay between L1-CAM, MycN and PTEN as well as the role played by PDGFR and VEGFR on tumorigenicity in neuroblastoma cells. We investigated the effect of L1-CAM knock-down (KD) and PDGFR/VEGFR inhibition with sunitinib malate (Sutent®) treatment on subsequent tumorsphere formation and cellular proliferation and migration in the MycN-amplified IMR-32 neuroblastoma cells. We further examined the effect of combined L1-CAM KD with Sutent treatment or radiotherapy on these cellular functions in our cells. Tumorsphere formation is one of the indicators of aggressiveness in malignant cancers, which was significantly inhibited in IMR-32 cells after L1-CAM KD or Sutent treatment, however, no synergistic effect was observed with dual treatments, rather L1-CAM KD alone showed a greater inhibition on tumorsphere formation compared to Sutent treatment alone. In addition, cellular proliferation and migration were significantly inhibited after L1-CAM KD in the IMR-32 cells with no synergistic effect observed on the rate of cell proliferation when combined with Sutent treatment. Again, L1-CAM KD alone exhibited greater inhibitory effect than Sutent treatment on cell proliferation. L1-CAM KD led to the simultaneous downregulation of MycN, but the upregulation of PTEN protein expression. Notably, radiotherapy (2 Gy) of the IMR-32 cells led to significant upregulation of both L1-CAM and MycN, which was abrogated with L1-CAM KD in our cells. In addition, L1-CAM KD radiosensitized the cells as exhibited by the synergistic effect on the reduction in cell proliferation compared to radiotherapy alone. Taken together, our data show the importance of L1-CAM interplay with MycN and PTEN on the MycN amplified neuroblastoma cell radioresistance, proliferation and motility.

View Figures

View References

1	Davidoff AM: Neuroblastoma. Semin Pediatr Surg. 21:2–14. 2012. View Article : Google Scholar : PubMed/NCBI
2	Stafman LL and Beierle EA: Cell proliferation in neuroblastoma. Cancers (Basel). 8:E132016. View Article : Google Scholar
3	Esiashvili N, Anderson C and Katzenstein HM: Neuroblastoma. Curr Probl Cancer. 33:333–360. 2009. View Article : Google Scholar
4	Colon NC and Chung DH: Neuroblastoma. Adv Pediatr. 58:297–311. 2011. View Article : Google Scholar : PubMed/NCBI
5	Brodeur GM and Nakagawara A: Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol Oncol. 14:111–116. 1992. View Article : Google Scholar : PubMed/NCBI
6	Bottino C, Dondero A, Bellora F, Moretta L, Locatelli F, Pistoia V, Moretta A and Castriconi R: Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches. Front Immunol. 5:562014. View Article : Google Scholar : PubMed/NCBI
7	Zimmerman KA, Yancopoulos GD, Collum RG, Smith RK, Kohl NE, Denis KA, Nau MM, Witte ON, Toran-Allerand D, Gee CE, et al: Differential expression of myc family genes during murine development. Nature. 319:780–783. 1986. View Article : Google Scholar : PubMed/NCBI
8	Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, et al: Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: A Children’s Oncology Group study. Br J Cancer. 113:57–63. 2015. View Article : Google Scholar : PubMed/NCBI
9	Schäfer MK and Altevogt P: L1CAM malfunction in the nervous system and human carcinomas. Cell Mol Life Sci. 67:2425–2437. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S and Altevogt P: L1CAM: A major driver for tumor cell invasion and motility. Cell Adhes Migr. 6:374–384. 2012. View Article : Google Scholar
11	Poplawski GH, Tranziska AK, Leshchyns’ka I, Meier ID, Streichert T, Sytnyk V and Schachner M: L1CAM increases MAP2 expression via the MAPK pathway to promote neurite outgrowth. Mol Cell Neurosci. 50:169–178. 2012. View Article : Google Scholar : PubMed/NCBI
12	Nakata A and Kamiguchi H: Serine phosphorylation by casein kinase II controls endocytic L1 trafficking and axon growth. J Neurosci Res. 85:723–734. 2007. View Article : Google Scholar : PubMed/NCBI
13	Lewandowski G and Steward O: AAVshRNA-mediated suppression of PTEN in adult rats in combination with salmon fibrin administration enables regenerative growth of corticospinal axons and enhances recovery of voluntary motor function after cervical spinal cord injury. J Neurosci. 34:9951–9962. 2014. View Article : Google Scholar : PubMed/NCBI
14	Schapira AH, Olanow CW, Greenamyre JT and Bezard E: Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: Future therapeutic perspectives. Lancet. 384:545–555. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wang Y and Schachner M: The intracellular domain of L1CAM binds to casein kinase 2α and is neuroprotective via inhibition of the tumor suppressors PTEN and p53. J Neurochem. 133:828–843. 2015. View Article : Google Scholar : PubMed/NCBI
16	Colombo F and Meldolesi J: L1-CAM and N-CAM: From adhesion proteins to pharmacological targets. Trends Pharmacol Sci. 36:769–781. 2015. View Article : Google Scholar : PubMed/NCBI
17	Friedli A, Fischer E, Novak-Hofer I, Cohrs S, Ballmer-Hofer K, Schubiger PA, Schibli R and Grünberg J: The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. Int J Biochem Cell Biol. 41:1572–1580. 2009. View Article : Google Scholar : PubMed/NCBI
18	Schröder C, Schumacher U, Fogel M, Feuerhake F, Müller V, Wirtz RM, Altevogt P, Krenkel S, Jänicke F and Milde-Langosch K: Expression and prognostic value of L1-CAM in breast cancer. Oncol Rep. 22:1109–1117. 2009.PubMed/NCBI
19	Son YS, Seong RH, Ryu CJ, Cho YS, Bae KH, Chung SJ, Lee B, Min JK and Hong HJ: Brief report: L1 cell adhesion molecule, a novel surface molecule of human embryonic stem cells, is essential for self-renewal and pluripotency. Stem Cells. 29:2094–2099. 2011. View Article : Google Scholar : PubMed/NCBI
20	Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB and Rich JN: Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 68:6043–6048. 2008. View Article : Google Scholar : PubMed/NCBI
21	Wachowiak R, Fiegel HC, Kaifi JT, Quaas A, Krickhahn A, Schurr PG, Erttmann R, Schachner M, Kluth D, Sauter G, et al: L1 is associated with favorable outcome in neuroblastomas in contrast to adult tumors. Ann Surg Oncol. 14:3575–3580. 2007. View Article : Google Scholar : PubMed/NCBI
22	Chong Y, Zhang J, Guo X, Li G, Zhang S, Li C, Jiao Z and Shao M: MicroRNA-503 acts as a tumor suppressor in osteosarcoma by targeting L1CAM. PLoS One. 9:e1145852014. View Article : Google Scholar : PubMed/NCBI
23	Weiswald LB, Bellet D and Dangles-Marie V: Spherical cancer models in tumor biology. Neoplasia. 17:1–15. 2015. View Article : Google Scholar : PubMed/NCBI
24	Mack SC, Hubert CG, Miller TE, Taylor MD and Rich JN: An epigenetic gateway to brain tumor cell identity. Nat Neurosci. 19:10–19. 2016. View Article : Google Scholar
25	Xie Q, Flavahan WA, Bao S and Rich J: The tailless root of glioma: cancer stem cells. Cell Stem Cell. 15:114–116. 2014. View Article : Google Scholar : PubMed/NCBI
26	Chakrabarti L, Wang BD, Lee NH and Sandler AD: A mechanism linking Id2-TGFβ crosstalk to reversible adaptive plasticity in neuroblastoma. PLoS One. 8:e835212013. View Article : Google Scholar
27	Chakrabarti L, Abou-Antoun T, Vukmanovic S and Sandler AD: Reversible adaptive plasticity: A mechanism for neuroblastoma cell heterogeneity and chemo-resistance. Front Oncol. 2:822012. View Article : Google Scholar : PubMed/NCBI
28	Abouantoun TJ, Castellino RC and MacDonald TJ: Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. J Neurooncol. 101:215–226. 2011. View Article : Google Scholar
29	London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, et al: Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol. 23:6459–6465. 2005. View Article : Google Scholar : PubMed/NCBI
30	Bondong S, Kiefel H and Erbe-Hoffmann N: Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation. Ann Oncol. 23:1795–1802. 2012. View Article : Google Scholar : PubMed/NCBI
31	Li S, Jo YS, Lee JH, Min JK, Lee ES, Park T, Kim JM and Hong HJ: L1 cell adhesion molecule is a novel independent poor prognostic factor of extrahepatic cholangiocarcinoma. Clin Cancer Res. 15:7345–7351. 2009. View Article : Google Scholar : PubMed/NCBI
32	Hai J, Zhu CQ, Bandarchi B, Wang YH, Navab R, Shepherd FA, Jurisica I and Tsao MS: L1 cell adhesion molecule promotes tumorigenicity and metastatic potential in non-small cell lung cancer. Clin Cancer Res. 18:1914–1924. 2012. View Article : Google Scholar : PubMed/NCBI
33	Linnemann D and Bock E: Expression of the cell adhesion molecules N-CAM and L1 in B16 melanoma cells. Med Biol. 64:345–349. 1986.PubMed/NCBI
34	Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A, Tilgen W, Reichrath J, Georg T, Altevogt P and Gutwein P: L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett. 189:237–247. 2003. View Article : Google Scholar
35	Linnemann D, Raz A and Bock E: Differential expression of cell adhesion molecules in variants of K1735 melanoma cells differing in metastatic capacity. Int J Cancer. 43:709–712. 1989. View Article : Google Scholar : PubMed/NCBI
36	Thies A, Schachner M, Moll I, Berger J, Schulze HJ, Brunner G and Schumacher U: Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer. 38:1708–1716. 2002. View Article : Google Scholar : PubMed/NCBI
37	Dillon LM and Miller TW: Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets. 15:65–79. 2014. View Article : Google Scholar : PubMed/NCBI
38	Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T, Barany F, Paty P, Notterman D, Domany E, et al: Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res. 67:7703–7712. 2007. View Article : Google Scholar : PubMed/NCBI
39	Boo YJ, Park JM, Kim J, Chae YS, Min BW, Um JW and Moon HY: L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol. 14:1703–1711. 2007. View Article : Google Scholar : PubMed/NCBI
40	Kaifi JT, Reichelt U, Quaas A, Schurr PG, Wachowiak R, Yekebas EF, Strate T, Schneider C, Pantel K, Schachner M, et al: L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol. 20:1183–1190. 2007. View Article : Google Scholar : PubMed/NCBI
41	Ben Q, An W, Fei J, Xu M, Li G, Li Z and Yuan Y: Downregulation of L1CAM inhibits proliferation, invasion and arrests cell cycle progression in pancreatic cancer cells in vitro. Exp Ther Med. 7:785–790. 2014.PubMed/NCBI
42	Raveh S, Gavert N and Ben-Ze’ev A: L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett. 282:137–145. 2009. View Article : Google Scholar : PubMed/NCBI
43	Keerthikumar S, Gangoda L, Liem M, Fonseka P, Atukorala I, Ozcitti C, Mechler A, Adda CG, Ang CS and Mathivanan S: Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes. Oncotarget. 6:15375–15396. 2015. View Article : Google Scholar : PubMed/NCBI
44	Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W, Rich JN and Bao S: L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J. 30:800–813. 2011. View Article : Google Scholar : PubMed/NCBI
45	Schaefer AW, Kamiguchi H, Wong EV, Beach CM, Landreth G and Lemmon V: Activation of the MAPK signal cascade by the neural cell adhesion molecule L1 requires L1 internalization. J Biol Chem. 274:37965–37973. 1999. View Article : Google Scholar : PubMed/NCBI
46	Cheng L, Lemmon S and Lemmon V: RanBPM is an L1-interacting protein that regulates L1-mediated mitogen-activated protein kinase activation. J Neurochem. 94:1102–1110. 2005. View Article : Google Scholar : PubMed/NCBI
47	Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn M, Godwin AK, et al: The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res. 68:1110–1118. 2008. View Article : Google Scholar : PubMed/NCBI